Successful respiratory immunization with dry powder live-attenuated measles virus vaccine in rhesus macaques

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 7, 2011, Pages 2987-2992

  Lin, Wen Hsuan ^a   Griffin, Diane E ^a   Rota, Paul A ^b   Papania, Mark ^b   Cape, Stephen P ^c   Bennett, David ^d   Quinn, Brian ^d   Sievers, Robert E ^c,d   Shermer, Charles ^e   Powell, Kenneth ^e   Adams, Robert J ^f   Godin, Steven ^g   Winston, Scott ^d  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d Aktiv Dry LLC   (United States)

^e BD Technologies   (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g Smithers Viscient   (United States)

Author keywords

Aerosol delivery; Antibody avidity; Multifunctional T cells; Protective immunity

Indexed keywords

MEASLES VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DRUG DELIVERY SYSTEM; DRY POWDER; HUMORAL IMMUNITY; IMMUNOGENICITY; MEASLES; MEASLES VACCINATION; NONHUMAN; POWDER INHALER; PRIORITY JOURNAL; RHESUS MONKEY; T LYMPHOCYTE;

ADMINISTRATION, INHALATION; ANALYSIS OF VARIANCE; ANIMALS; DRY POWDER INHALERS; ENZYME-LINKED IMMUNOSPOT ASSAY; MACACA MULATTA; MEASLES; MEASLES VACCINE; MEASLES VIRUS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VACCINES, ATTENUATED; VIREMIA;

MACACA; MACACA MULATTA; MEASLES VIRUS;

EID: 79952598781     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1017334108     Document Type: Article

References (45)

1. Centers for Disease Control and Prevention (CDC) (2009) Global measles mortality, 2000-2008. MMWR Morb Mortal Wkly Rep 58:1321-1326.
2. Melnick JL (1996) Thermostability of poliovirus and measles vaccines. Dev Biol Stand 87:155-160.
3. Sabin AB (1992) My last will and testament on rapid elimination and ultimate global eradication of poliomyelitis and measles. Pediatrics 90:162-169.
4. Sabin AB, et al. (1983) Successful immunization of children with and without maternal antibody by aerosolized measles vaccine. I. Different results with undiluted human diploid cell and chick embryo fibroblast vaccines. JAMA 249:2651-2662.
5. Sabin AB (1991) Measles, killer of millions in developing countries: Strategy for rapid elimination and continuing control. Eur J Epidemiol 7:1-22.
6. Cutts FT, Clements CJ, Bennett JV (1997) Alternative routes of measles immunization: a review. Biologicals 25:323-338. (Pubitemid 27453255)
7. Dilraj A, et al. (2000) Response to different measles vaccine strains given by aerosol and subcutaneous routes to schoolchildren: A randomised trial. Lancet 355:798-803. (Pubitemid 30128820)
8. Bennett JV, et al. (2002) Aerosolized measles and measles-rubella vaccines induce better measles antibody booster responses than injected vaccines: Randomized trials in Mexican schoolchildren. Bull World Health Organ 80:806-812. (Pubitemid 35246731)
9. Díaz-Ortega JL, Bennett JV, Castañeda D, Martinez D, de Castro JF (2010) Antibody persistence in young adults 1 year after MMR immunization by aerosol or by subcutaneous route. Vaccine 28:7228-7232.
10. Diaz-Ortega JL, et al. (2010) Successful seroresponses to measles and rubella following aerosolized Triviraten vaccine, but poor response to aerosolized mumps (Rubini) component: Comparisons with injected MMR. Vaccine 28:692-698.
11. Omer SB, Hiremath GS, Halsey NA (2010) Respiratory administration of measles vaccine. Lancet 375:706-708.
12. Hiremath GS, Omer SB (2005) A meta-analysis of studies comparing the respiratory route with the subcutaneous route of measles vaccine administration. Hum Vaccin 1:30-36.
13. Low N, Kraemer S, Schneider M, Restrepo AM (2008) Immunogenicity and safety of aerosolized measles vaccine: Systematic review and meta-analysis. Vaccine 26:383-398.
14. Wong-Chew RM, et al. (2006) Immunogenicity of aerosol measles vaccine given as the primary measles immunization to nine-month-old Mexican children. Vaccine 24:683-690. (Pubitemid 43017835)
15. Wong-Chew RM, et al. (2004) Induction of cellular and humoral immunity after aerosol or subcutaneous administration of Edmonston-Zagreb measles vaccine as a primary dose to 12-month-old children. J Infect Dis 189:254-257. (Pubitemid 38147249)
16. Auwaerter PG, et al. (1999) Measles virus infection in rhesus macaques: Altered immune responses and comparison of the virulence of six different virus strains. J Infect Dis 180:950-958. (Pubitemid 30070173)
17. Cape SP, et al. (2008) Preparation of active proteins, vaccines and pharmaceuticals as fine powders using supercritical or near-critical fluids. Pharm Res 25:1967-1990.
18. Burger JL, et al. (2008) Stabilizing formulations for inhalable powders of live-attenuated measles virus vaccine. J Aerosol Med Pulm Drug Deliv 21:25-34.
19. Coates AL, et al. (2000) Accounting for radioactivity before and after nebulization of tobramycin to insure accuracy of quantification of lung deposition. J Aerosol Med 13:169-178.
20. Clay MM, Pavia D, Newman SP, Clarke SW (1983) Factors influencing the size distribution of aerosols from jet nebulisers. Thorax 38:755-759. (Pubitemid 13019505)
21. Mikszta JA, et al. (2005) Protective immunization against inhalational anthrax: A comparison of minimally invasive delivery platforms. J Infect Dis 191:278-288. (Pubitemid 40096387)
22. Sullivan VJ, Mikszta JA, Laurent P, Huang J, Ford B (2006) Noninvasive delivery technologies: Respiratory delivery of vaccines. Expert Opin Drug Deliv 3:87-95. (Pubitemid 43056393)
23. Huang J, et al. (2009) Protective immunity in mice achieved with dry powder formulation and alternative delivery of plague F1-V vaccine. Clin Vaccine Immunol 16:719-725.
24. Huang J, et al. (2007) Intranasal administration of dry powder anthrax vaccine provides protection against lethal aerosol spore challenge. Hum Vaccin 3:90-93. (Pubitemid 46717375)
25. Slifka MK, Antia R, Whitmire JK, Ahmed R (1998) Humoral immunity due to long-lived plasma cells. Immunity 8:363-372. (Pubitemid 28188896)
26. Seder RA, Darrah PA, Roederer M (2008) T-cell quality in memory and protection: Implications for vaccine design. Nat Rev Immunol 8:247-258. (Pubitemid 351432801)
27. Darrah PA, et al. (2007) Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 13:843-850. (Pubitemid 47038186)
28. van Binnendijk RS, van der Heijden RW, van Amerongen G, UytdeHaag FG, Osterhaus AD (1994) Viral replication and development of specific immunity in macaques after infection with different measles virus strains. J Infect Dis 170:443-448. (Pubitemid 24226379)
29. de Vries RD, et al. (2010) In vivo tropism of attenuated and pathogenic measles virus expressing green fluorescent protein in macaques. J Virol 84:4714-4724.
30. de Swart RL, et al. (2006) Aerosol measles vaccination in macaques: Preclinical studies of immune responses and safety. Vaccine 24:6424-6436. (Pubitemid 44331997)
31. Simon JK, et al. (2007) A clinical study to assess the safety and immunogenicity of attenuated measles vaccine administered intranasally to healthy adults. Hum Vaccin 3:54-58. (Pubitemid 46493606)
32. de Swart RL, et al. (2007) Measles vaccination of macaques by dry powder inhalation. Vaccine 25:1183-1190. (Pubitemid 46027344)
33. Coates AL, Tipples G, Leung K, Gray M, Louca E; WHO Product Development Group for Measles Aerosol Vaccine (2006) How many infective viral particles are necessary for successful mass measles immunization by aerosol? Vaccine 24:1578-1585.
34. Beck SE, et al. (2002) Deposition and expression of aerosolized rAAV vectors in the lungs of Rhesus macaques. Mol Ther 6:546-554. (Pubitemid 35214877)
35. Amanna IJ, Carlson NE, Slifka MK (2007) Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 357:1903-1915.
36. +) lymphocytes in control and clearance of measles virus infection of rhesus monkeys. J Virol 77:4396-4400.
37. Pan CH, et al. (2010) A chimeric alphavirus replicon particle vaccine expressing the hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques from measles. J Virol 84:3798-3807.
38. Pan CH, et al. (2005) Modulation of disease, T cell responses, and measles virus clearance in monkeys vaccinated with H-encoding alphavirus replicon particles. Proc Natl Acad Sci USA 102:11581-11588.
39. Sellers SP, Clark GS, Sievers RE, Carpenter JF (2001) Dry powders of stable protein formulations from aqueous solutions prepared using supercritical CO(2)-assisted aerosolization. J Pharm Sci 90:785-797. (Pubitemid 32530452)
40. Sievers RE, et al. (2007) Near critical fluid micronization of stabilized vaccines, antibiotics and anti-virals. J Supercrit Fluids 42:385-391. (Pubitemid 47039202)
41. Ono N, et al. (2001) Measles viruses on throat swabs from measles patients use signaling lymphocytic activation molecule (CDw150) but not CD46 as a cellular receptor. J Virol 75:4399-4401. (Pubitemid 32410152)
42. Hummel KB, Lowe L, Bellini WJ, Rota PA (2006) Development of quantitative gene-specific real-time RT-PCR assays for the detection of measles virus in clinical specimens. J Virol Methods 132:166-173. (Pubitemid 43220176)
43. Boddicker JD, et al. (2007) Real-time reverse transcription-PCR assay for detection of mumps virus RNA in clinical specimens. J Clin Microbiol 45:2902-2908. (Pubitemid 47417333)
44. Cohen BJ, Audet S, Andrews N, Beeler J; WHO Working Group on Measles Plaque Reduction Neutralization Test (2007) Plaque reduction neutralization test for measles antibodies: Description of a standardised laboratory method for use in immunogenicity studies of aerosol vaccination. Vaccine 26:59-66. (Pubitemid 50008088)
45. Hummel KB, Erdman DD, Heath J, Bellini WJ (1992) Baculovirus expression of the nucleoprotein gene of measles virus and utility of the recombinant protein in diagnostic enzyme immunoassays. J Clin Microbiol 30:2874-2880.